Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Medial EarlySign Expands U.S. Footprint With Appointment of Senior Executives

VP of Sales in North America and Chief Customer Success Officer Increase Reach and Adoption of AI Disease Management Solutions

Medial EarlySign (, a leader in machine learning-based solutions to improve disease management, announced the appointment of two senior executives in its Boston-area office to meet growing U.S. demand for its predictive analytics solutions. Patrick Wells, formerly with IBM Watson Health, has been appointed Chief Customer Success Officer, and veteran Brandon Wilcher has been hired as Vice President of Sales in the North American Region.

These new hires highlight Medial EarlySign’s success in implementing its machine learning solutions within healthcare organizations as well as its commitment to ensuring organizations receive the highest quality insights to assist them in improving patients’ health, provide proactive care and aid in effective resource allocation.

Read More: The Top 5 “Recipes” That Give AI Projects a Higher Likelihood of Success

“Medial EarlySign’s proprietary machine-learning based technology is increasingly sought after in the U.S. and around the world, and we welcome Patrick and Brandon to help us meet the growing demand for our solutions,” said Ori Geva, CEO and Co-founder of Medial EarlySign. “We are confident and excited for both hires to further our continued expansion and success of implementing our AI-based, patient-specific treatment prioritization platforms for lower GI disorders, diabetes and other life-threatening conditions.”

Related Posts
1 of 1,025

Wells brings over 18 years of experience in managing complex solutions and delivering strategic programs to provide clients with actionable insights that improve healthcare initiatives. Most recently, he served as Vice President of Advisory Services at IBM Watson Health and Deloitte & Touche, where he was instrumental in leading multiple complex client engagements. He also held leadership roles at Axentis (acquired by Wolters Kluwer) and Per-Se Technologies (acquired by McKesson) where he managed strategic client relationships.

Read More:  Fluor Uses IBM Watson to Deliver Predictive Analytics Capability for Megaprojects

“Medial EarlySign has emerged as a key player in health AI and predictive analytics, and is one of the few companies whose algorithms have been validated in clinical practice and analyzed in multiple peer-reviewed studies,” said Wells. “I am excited to join Medial’s team and culture. I was impressed with a culture focused on excellence and bringing healthcare organizations practical, easy to implement solutions with the potential to impact millions of lives.”

Wilcher joins EarlySign from Wolters Kluwer Health, where he was the top sales producer in the Clinical Effectiveness business unit. Prior to that, he served as a Senior Director for Merritt Hawkins, a division of AMN Healthcare (NYSE: AMN), and handled business development efforts at Skylight Healthcare Systems, a fully-integrated patient engagement and education solution.

“Predictive analytics will provide an invaluable tool in improving care delivery through the early identification of high-risk patients,” said Wilcher. “I am delighted to join Medial EarlySign and assist in spreading its powerful AI solutions to healthcare organizations and their physicians across the United States.”

Read More: The AI Gold Rush: How to Make Money off AI and Machine Learning!

Leave A Reply

Your email address will not be published.